Assignee
ENGMAB SARL
CH·3 granted patents·8 pending applications·20 citations·filing 2016–2022
Top patents by PatentIndex Score
11 records- 0194US10683369B2Monoclonal antibodies against BCMAENGMAB SARL·Filed 2016·Granted Jun 16, 2020·14 cites·21 claims
- 0282US11124577B2Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myelomaENGMAB SARL·Filed 2017·Granted Sep 21, 2021·5 cites·8 claims
- 0380US10851171B2Method for the selection of antibodies against BCMAENGMAB SARL·Filed 2018·Granted Dec 1, 2020·1 cites·4 claims
- 0473US2023322957A1Monoclonal antibodies against bcmaENGMAB SARL·Filed 2022·Application pending·0 cites
- 0568US2021070873A1Method for the selection of antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 0664US2020385471A1Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseasesENGMAB SARL·Filed 2020·Application pending·0 cites
- 0762US2020283545A1Monoclonal antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 0860US2022017631A1Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myelomaENGMAB SARL·Filed 2021·Application pending·0 cites
- 0960US2022002427A1Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myelomaENGMAB SARL·Filed 2021·Application pending·0 cites
- 1056US2020255521A1Bispecific antibodies against cd3epsilon and ror1ENGMAB SARL·Filed 2020·Application pending·0 cites
- 1147US2023364230A1Combination therapy for cancerENGMAB SARL·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →